Anti-nerve growth factor

Allison Gandey, Roger Chou

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Generic Names: nerve growth factor antibodies (anti-NGF) Trade/Proprietary Names: Tanezumab™, Antibody PG110, JNJ-42160443 Drug Class: monoclonal antibody Manufacturers: Pfizer Pharmaceuticals, 235 East 42nd Street, New York, NY 10017; PanGenetics BV, Heath House, Princes Mews, Royston, SG8 9RT, UK; Johnson and Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933 Description Management of chronic pain is often challenging since commonly prescribed analgesics do not have direct effects on damaged nerves, but, rather, nonspecific effects on pain receptors and other mediators of pain. Neurotoxins are a new class of medications that are being evaluated as potential analgesics. Using these medications, researchers hope to achieve pain relief by suppressing the activity of injured nerve tissue and directly targeting the source of some types of chronic pain. A challenge in developing these medications is that in addition to affecting nerves causing pain, they could also damage other nerves, including those in the brain and spinal cord. Neurotoxins could therefore cause serious harm related to unintended nerve damage, and are undergoing careful testing to understand how well they selectively affect already damaged nerves. Anti-nerve growth factor is the first highly selective neurotoxin to be investigated for use in humans. Discovered in the 1950s, investigators found that this immunotoxin stunts neural growth. Researchers Rita Levi-Montalcini and Victor Hamburger observed that a substantial increase in the size of sympathetic ganglia coincided with the extensive branching of sympathetic axonal terminals in tumors. They reasoned that tumors were releasing a neurotrophin - a protein that promotes the growth and development of neurons.

Original languageEnglish (US)
Title of host publicationThe Essence of Analgesia and Analgesics
PublisherCambridge University Press
Pages512-514
Number of pages3
ISBN (Electronic)9780511841378
ISBN (Print)9780521144506
DOIs
StatePublished - Jan 1 2010

Fingerprint

Neurotoxins
Nerve Growth Factor
Research Personnel
Chronic Pain
Names
Analgesics
Hope
New Brunswick
Immunotoxins
Pain
Nerve Tissue
Nociceptors
Sympathetic Ganglia
Nerve Growth Factors
Neuralgia
Growth and Development
Pharmaceutical Preparations
Anti-Idiotypic Antibodies
Neoplasms
Spinal Cord

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gandey, A., & Chou, R. (2010). Anti-nerve growth factor. In The Essence of Analgesia and Analgesics (pp. 512-514). Cambridge University Press. https://doi.org/10.1017/CBO9780511841378.131

Anti-nerve growth factor. / Gandey, Allison; Chou, Roger.

The Essence of Analgesia and Analgesics. Cambridge University Press, 2010. p. 512-514.

Research output: Chapter in Book/Report/Conference proceedingChapter

Gandey, A & Chou, R 2010, Anti-nerve growth factor. in The Essence of Analgesia and Analgesics. Cambridge University Press, pp. 512-514. https://doi.org/10.1017/CBO9780511841378.131
Gandey A, Chou R. Anti-nerve growth factor. In The Essence of Analgesia and Analgesics. Cambridge University Press. 2010. p. 512-514 https://doi.org/10.1017/CBO9780511841378.131
Gandey, Allison ; Chou, Roger. / Anti-nerve growth factor. The Essence of Analgesia and Analgesics. Cambridge University Press, 2010. pp. 512-514
@inbook{9429cc40c9764d78839a1a8173c1effb,
title = "Anti-nerve growth factor",
abstract = "Generic Names: nerve growth factor antibodies (anti-NGF) Trade/Proprietary Names: Tanezumab™, Antibody PG110, JNJ-42160443 Drug Class: monoclonal antibody Manufacturers: Pfizer Pharmaceuticals, 235 East 42nd Street, New York, NY 10017; PanGenetics BV, Heath House, Princes Mews, Royston, SG8 9RT, UK; Johnson and Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933 Description Management of chronic pain is often challenging since commonly prescribed analgesics do not have direct effects on damaged nerves, but, rather, nonspecific effects on pain receptors and other mediators of pain. Neurotoxins are a new class of medications that are being evaluated as potential analgesics. Using these medications, researchers hope to achieve pain relief by suppressing the activity of injured nerve tissue and directly targeting the source of some types of chronic pain. A challenge in developing these medications is that in addition to affecting nerves causing pain, they could also damage other nerves, including those in the brain and spinal cord. Neurotoxins could therefore cause serious harm related to unintended nerve damage, and are undergoing careful testing to understand how well they selectively affect already damaged nerves. Anti-nerve growth factor is the first highly selective neurotoxin to be investigated for use in humans. Discovered in the 1950s, investigators found that this immunotoxin stunts neural growth. Researchers Rita Levi-Montalcini and Victor Hamburger observed that a substantial increase in the size of sympathetic ganglia coincided with the extensive branching of sympathetic axonal terminals in tumors. They reasoned that tumors were releasing a neurotrophin - a protein that promotes the growth and development of neurons.",
author = "Allison Gandey and Roger Chou",
year = "2010",
month = "1",
day = "1",
doi = "10.1017/CBO9780511841378.131",
language = "English (US)",
isbn = "9780521144506",
pages = "512--514",
booktitle = "The Essence of Analgesia and Analgesics",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Anti-nerve growth factor

AU - Gandey, Allison

AU - Chou, Roger

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Generic Names: nerve growth factor antibodies (anti-NGF) Trade/Proprietary Names: Tanezumab™, Antibody PG110, JNJ-42160443 Drug Class: monoclonal antibody Manufacturers: Pfizer Pharmaceuticals, 235 East 42nd Street, New York, NY 10017; PanGenetics BV, Heath House, Princes Mews, Royston, SG8 9RT, UK; Johnson and Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933 Description Management of chronic pain is often challenging since commonly prescribed analgesics do not have direct effects on damaged nerves, but, rather, nonspecific effects on pain receptors and other mediators of pain. Neurotoxins are a new class of medications that are being evaluated as potential analgesics. Using these medications, researchers hope to achieve pain relief by suppressing the activity of injured nerve tissue and directly targeting the source of some types of chronic pain. A challenge in developing these medications is that in addition to affecting nerves causing pain, they could also damage other nerves, including those in the brain and spinal cord. Neurotoxins could therefore cause serious harm related to unintended nerve damage, and are undergoing careful testing to understand how well they selectively affect already damaged nerves. Anti-nerve growth factor is the first highly selective neurotoxin to be investigated for use in humans. Discovered in the 1950s, investigators found that this immunotoxin stunts neural growth. Researchers Rita Levi-Montalcini and Victor Hamburger observed that a substantial increase in the size of sympathetic ganglia coincided with the extensive branching of sympathetic axonal terminals in tumors. They reasoned that tumors were releasing a neurotrophin - a protein that promotes the growth and development of neurons.

AB - Generic Names: nerve growth factor antibodies (anti-NGF) Trade/Proprietary Names: Tanezumab™, Antibody PG110, JNJ-42160443 Drug Class: monoclonal antibody Manufacturers: Pfizer Pharmaceuticals, 235 East 42nd Street, New York, NY 10017; PanGenetics BV, Heath House, Princes Mews, Royston, SG8 9RT, UK; Johnson and Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933 Description Management of chronic pain is often challenging since commonly prescribed analgesics do not have direct effects on damaged nerves, but, rather, nonspecific effects on pain receptors and other mediators of pain. Neurotoxins are a new class of medications that are being evaluated as potential analgesics. Using these medications, researchers hope to achieve pain relief by suppressing the activity of injured nerve tissue and directly targeting the source of some types of chronic pain. A challenge in developing these medications is that in addition to affecting nerves causing pain, they could also damage other nerves, including those in the brain and spinal cord. Neurotoxins could therefore cause serious harm related to unintended nerve damage, and are undergoing careful testing to understand how well they selectively affect already damaged nerves. Anti-nerve growth factor is the first highly selective neurotoxin to be investigated for use in humans. Discovered in the 1950s, investigators found that this immunotoxin stunts neural growth. Researchers Rita Levi-Montalcini and Victor Hamburger observed that a substantial increase in the size of sympathetic ganglia coincided with the extensive branching of sympathetic axonal terminals in tumors. They reasoned that tumors were releasing a neurotrophin - a protein that promotes the growth and development of neurons.

UR - http://www.scopus.com/inward/record.url?scp=85012195775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012195775&partnerID=8YFLogxK

U2 - 10.1017/CBO9780511841378.131

DO - 10.1017/CBO9780511841378.131

M3 - Chapter

SN - 9780521144506

SP - 512

EP - 514

BT - The Essence of Analgesia and Analgesics

PB - Cambridge University Press

ER -